A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series

Vera K Schmit-Eilenberger

Augenklinik Städtisches Klinikum,
Karlsruhe, Baden-Württemberg,
Germany

Background: Iluvien® is a novel, nonbiodegradable, sustained-release drug delivery system (0.2 µg/d fluocinolone acetonide [FAC]) indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema (DME), considered insufficiently responsive to available therapies.

Objective: To evaluate the safety and efficacy of 190-µg FAC implant in patients with chronic DME refractory to other medical treatment options in a clinical setting.

Methods: Retrospective registry data were collected by using standard case report forms (CRFs). Prior to intravitreal injection of the FAC implant, all patients were treated either with a vascular endothelial growth factor (VEGF) antagonist and/or a steroid (triamcinolone, dexamethasone implant). Patients were excluded from receiving FAC if they had a known history of elevated intraocular pressure (IOP) following corticosteroid therapy, glaucoma, ocular hypertension, or any contraindications cited in the summary of product characteristics. Best-corrected visual acuity (BCVA) was the main study parameter. Central fovea thickness (CFT) and IOP were measured concurrently. These parameters were recorded prior to and after the injection of the 190-µg FAC implant (between 1 week and 9 months). Injections were performed between May 2013 and March 2014.

Results: Fifteen eyes from ten patients were treated. Thirteen eyes (nine patients) were pseudophakic, and seven eyes (five patients) were vitrectomized prior to receiving therapy. BCVA improved in eleven eyes (73.3%), remained unchanged in two eyes (13.3%), and decreased slightly in two eyes (13.3%) at the last follow-up visit versus baseline levels. IOP increased in two patients and was controlled using fixed-combination of IOP-lowering eyedrops or sectorial cyclocryotherapy (n=1).

Conclusion: The 190-µg FAC implant was efficacious and showed a favorable benefit-to-risk profile in the patient population with chronic DME of this case series that were refractory to other therapies. The longer-term efficacy and safety in a real-life setting is still being assessed in this center. FAC may offer an important treatment option for patients with chronic DME refractory to other treatment options.

Keywords: fluocinolone acetonide, corticosteroid, diabetic macular edema, intravitreal implant, best-corrected visual acuity

Correspondence: Vera K Schmit-Eilenberger

Augenklinik Städtisches Klinikum,
Moltkestraße 90, D-76133 Karlsruhe,
Baden-Württemberg, Germany
Tel +49 721 974 2001
Fax +49 721 974 2009
Email dr.schmit-eilenberger@email.de

Introduction

Diabetic macular edema (DME) is the most common cause of reduced visual acuity in patients with diabetes. It could be shown that 20.1% of patients with type 1 diabetes,

25.4% with type 2 diabetes using insulin, and 13.9% with type 2 diabetes, not using insulin respectively, develop DME within a 10-year time period.¹ The global prevalence of diabetic retinopathy among individuals with diabetes is around 35%, with DME present in 6.8%.² Without treatment, nearly half of these patients developing DME will lose two or more lines of visual acuity within 2 years.³ It is well established that the incidence of DME increases with the duration of diabetes, the severity of retinopathy, and with increasing levels of glycosylated hemoglobin.^{4–7} Many interrelated pathways are linked to the cellular damage from hyperglycemia and hypoxia affecting the blood–retina barrier (BRB), including angiogenic growth factors and inflammatory cytokines. Glucocorticoids modulate multiple pathways to exert a therapeutic effect in DME. Recently, with the better understanding of the pathophysiology of DME and the discovery of the critical role played by the inflammatory cascade, many physicians have employed the use of corticosteroids to treat this sometimes relapsing or refractory disease.^{8–11} Corticosteroids have a direct angiostatic effect, suppress group II phospholipase A2, and block the inflammatory response.^{12,13} Furthermore corticosteroids have been shown to inhibit the expression of vascular endothelial growth factor (VEGF).^{14–16} By applying a drug directly into the vitreous, the BRB is bypassed and therapeutic intraocular levels can be achieved with doses of corticosteroids even at a submicrogram level.¹⁷ Intravitreal injections of corticosteroids, such as triamcinolone acetonide, have been shown to be beneficial in the treatment of patients with DME.^{18,19} It could be shown that intravitreal triamcinolone (4 mg) appeared to reduce the risk of diabetic retinopathy over a time period of 3 years.²⁰ Furthermore, it could be shown that over a time period of 4 months mean visual acuity was better in patients with DME receiving 4 mg triamcinolone as compared to triamcinolone 1 mg or focal/grid laser photocoagulation. Interestingly visual acuity was better in the laser treatment arm as compared to both medical treatment arms (triamcinolone 1 and 4 mg) after 16 months and up till 2 years of the study extension period.²¹ Triamcinolone – even if the substance is used for the medical treatment of DME – is not approved and marketed for the treatment of this eye disease. One major disadvantage of applying triamcinolone into the vitreous is that frequent injections are needed.²¹ To solve this issue, microimplants have been developed, which offer the advantage of a sustained release of the corticosteroid and thus reduce the number of procedures required to maintain therapeutic levels of the drug over a longer time period. Iluvien® (Alimera Sciences Inc., Alpharetta, GA, USA) is

an intravitreal, nonbioerodable microimplant containing the corticosteroid fluocinolone acetonide (FAc). This implant is made of polyimide and measures 3.5×0.37 mm. It is administered into the vitreous using a preloaded 25-gauge inserter, and once injected the microimplant continuously releases a low dose of FAc into the vitreous (0.2 µg/d FAc) that lasts for up to 36 months.²² FAc is indicated for the treatment of vision impairment associated with chronic DME, considered insufficiently responsive to available therapies.²³ The product is licensed in a number of European countries and was recently approved in the US by the FDA. Campochiaro et al²⁴ reported combined 3-year results of two pivotal studies with FAc in patients with chronic DME. In the FAME (Fluocinolone Acetonide in patients with diabetic Macular Edema) studies they evaluated 953 eyes of patients with persistent DME after one or more laser therapy treatments, randomized 1:2:2 for sham injection (n=185), low-dose FAc implant (0.2 µg/d, n=375), or high-dose FAc implant (0.5 µg/d FAc, n=393). At 36 months, 27.8% (high dose) and 28.7% (low dose) of all implant-treated eyes versus 18.9% of sham eyes demonstrated an improvement of 15 or more letters ($P=0.018$). In addition, preplanned subgroup analysis showed a significant and increased benefit, especially in patients with chronic DME.²⁵ Chronic DME was defined by a duration of the disease of ≥ 3 years. In this typically difficult-to-treat patient population, a gain of ≥ 15 letters was achieved by 34.0% of patients treated with FAc 0.2 µg/d versus 13.4 in the sham group. Known side effects of corticosteroid therapy are cataract formation and an increase of intraocular pressure (IOP). Indeed, in the FAME studies, four out of five patients underwent cataract surgery. Also, a rise in IOP that required IOP lowering drops was observed in 38.4% of the patients and 4.8% of these patients required an incisional IOP lowering procedure. The objective of this study was to collect a series of cases to evaluate the effects of 190-µg FAc implant in a real-life setting. Ten patients with chronic DME refractory to other medical treatment options, such as VEGF antagonists and/or intravitreal corticosteroids (triamcinolone, dexamethasone), were evaluated. Changes in best-corrected visual acuity (BCVA), central fovea thickness (CFT), and morphological improvements of the DME were analyzed. Adverse events (AEs) were assessed and form the basis of this report.

Methods

This was a retrospective registry study involving all eyes of the site (15 eyes from ten patients) treated with the 190-µg FAc implant between May 2013 and March 2014. Thus, this

series describes both, early and longer-term results of all patients with DME of the site treated with FAc within this time period. Persistent clinical DME was defined as retinal thickening and hard exudates within 500 μm of the macular center and the occurrence of hard exudates within this area. If spectral domain optical coherence tomography (OCT) data were available, DME was also defined as a CFT of $>250 \mu\text{m}$. The study was approved by the local ethics committee. Informed consent was gained from all patients, which enabled the collection and evaluation of individual patient data and the publication of anonymized patient data. All data were collected using standardized case report forms (CRFs).

All procedures were performed in an aseptic operating room under topical anesthesia by the same physician. The recommended technique for intraocular injection of the implant is as follows: the patient was prepared in an operating room with the same standards as followed for intraocular procedures. Whilst maintaining aseptic conditions the cap protecting the needle was carefully removed. The intravitreal injection of 190- μg FAc implant was performed by using the preloaded injector with a 25-gauge needle. The implant was injected inferotemporally and inserted into the vitreous of the eye. All patients were examined pre- and postoperatively on day 1, and the following parameters were assessed at each follow-up visit: BCVA, anterior chamber reaction, IOP, and fundus evaluation by indirect ophthalmoscopy. Complete ocular examination was performed at each follow-up visit. Due to the retrospective character of this case series, OCT (Cirrus 1, Carl Zeiss Meditech, Dublin, CA, USA) data were available for most but not all patients. Angiographic examinations were performed in all patients, thus macular edemas were detected either by OCT and/or fluorescence angiography. Determination of BCVA (measured on a decimal scale) was done thoroughly and refraction was done at each visit.

Patients with DME who met the following criteria were included: persistent clinically significant DME involving the center of the fovea, DME refractory to other medical treatment options (intravitreal VEGF antagonists and/or corticosteroid injections), ability to give informed consent.

Exclusion criteria were a history of corticosteroid-responsive IOP increase and the contraindications listed in the summary of product characteristics for Iluvien®.

The main outcome measure was BCVA at all follow-up visits compared to baseline. Secondary outcome measures included change in CFT on OCT, changes in IOP (Goldmann applanation tonometry), evaluation of the fundus

by fluorescence angiography (Spectralis, Heidelberg Engineering, Heidelberg, Germany), and development of any side effects resulting from the intravitreal injection of the 190- μg FAc implant.

Results

Patients

Fifteen eyes of nine male and one female patients with refractory chronic DME were treated with 190- μg FAc implant. The mean age of the patients was 69.2 years (range: 52–83 years). Nine patients were pseudophakic at baseline and one patient (patient number 1) suffered from a bilateral cataract which was removed 5–6 weeks after the injection of the FAc implant. Seven eyes (five patients) had a history of vitrectomy. At baseline, BCVA was in the range of 0.1–0.6 and the CFT was between 291 and 729 μm . Baseline IOP ranged between 12 and 19 mmHg (Table 1). All patients/eyes had been previously treated with VEGF antagonists (ranibizumab 0.5 mg, bevacizumab 1.25 mg) and/or corticosteroids (triamcinolone 4–25 mg, dexamethasone implant 700 μg) prior to initiation of the treatment with FAc, and had not responded sufficiently. Details for all patients, eyes, and the history of prior medical treatments for DME are shown in Table 2 as well as the numbers of injections. The follow-up period for all patients/eyes ranged between 2 and 37 weeks (Table 3). Table 3 summarizes the results for the development of BCVA, CFT, and IOP for all patients/eyes showing the baseline values and the last reading for each of these parameters.

Best-corrected visual acuity (BCVA)

BCVA improved at the last follow-up visit in eleven of 15 eyes (ie, 73.3% of cases) versus baseline. The mean gain in visual acuity, for all 15 eyes treated, was $+0.19 \pm 0.24$ (from a starting value of 0.25 ± 0.13) with a range

Table 1 Patient demographics and baseline values

Patients (n)	10
Eyes (n)	15
Mean age, (years) [range]	69.2 [52–83]
SD	9.5
Sex	
Male, n (%)	9 (90.0)
Female, n (%)	1 (10.0)
BCVA at baseline – range	0.1–0.6
CFT (μm)^a at baseline – range	291–729
IOP (mmHg) at baseline – range	12–19

Note: ^aFor five eyes no baseline values for CFT were taken.

Abbreviations: BCVA, best-corrected visual acuity; CFT, central fovea thickness; IOP, intraocular pressure; SD, standard deviation.

Table 2 Individual patients: age, sex, best-corrected visual acuity (BCVA) at baseline, and prior medical treatments

Patient number	Sex (m/f)	Age (years)	Eye	BCVA at baseline	Prior medical treatment	
					VEGF-antagonists	Corticosteroids
1	m	52	RE	0.25	Ran (3)	Tri (1) [10 mg], Dex (1)
			LE	0.25	Ran (3)	Tri (1) [10 mg], Dex (1)
2	f	64	RE	0.25	Bev (4), Ran (2)	
			LE	0.2	Bev (3)	
3	m	72	RE	0.3	Bev (14), Ran (5)	Tri (1) [4 mg], Tri (6) [25 mg]
			LE	0.6	Bev (15), Ran (4)	Tri (1) [10 mg], Tri (6) [25 mg]
4	m	83	LE	0.1	Ran (3), Bev (1)	Tri (1) [10 mg]
5	m	75	LE	0.4	Ran (3)	
6	m	68	RE	0.32	Bev (3)	Tri (1) [4 mg], Tri (1) [10 mg]
7	m	77	LE	0.1	Ran (7), Bev (2)	Tri (2) [10 mg]
8	m	76	RE	0.2	Ran (6), Bev (1)	Tri (1) [4 mg]
9	m	57	RE	0.3	Bev (4), Ran (5)	Tri (4) [10 mg], Tri (1) [25 mg]
			LE	0.25	Bev (6), Ran (5)	Tri (4) [10 mg], Tri (1) [25 mg]
10	m	68	RE	0.1	Bev (9), Ran (6)	Tri (7) [10 mg], Tri (2) [25 mg], Dex (1)
			LE	0.1	Ran (5), Bev (7)	Tri (2) [10 mg], Dex (2)

Notes: Numbers in parentheses indicate the number of injections. Squared brackets indicate dosage.

Abbreviations: Bev, bevacizumab (1.25 mg); Dex, dexamethasone implant (700 µg); f, female; LE, left eye; m, male; Ran, ranibizumab (0.5 mg); RE, right eye; Tri, triamcinolone; VEGF, vascular endothelial growth factor.

between -0.1 and $+0.75$. In three eyes, BCVA was unchanged versus baseline, and in two eyes decreased slightly (-0.1 and -0.05 , patient 8 and 10 respectively; Table 3). Figure 1 shows the development of BCVA for each individual patient at baseline versus the last follow-up visit. The gain in visual acuity was independent from the prior treatment, as BCVA improved in cases where patients had been treated previously with VEGF antagonists, corticosteroids, or both (Table 3).

Central fovea thickness (CFT)

Baseline values for CFT were available for ten of the 15 eyes. CFT at baseline ranged between 291 and 729 µm (mean CFT at baseline $\pm$ SD: 509.4 ± 150.7 µm). After initiation of treatment with FAc, CFT declined in all ten eyes on average by -206.3 µm (mean CFT last follow-up visit $\pm$ SD: 303.1 ± 82.1 µm), for which CFT data were available. Figure 2 shows the development of CFT for each individual patient at baseline versus the

Table 3 Individual patients: BCVA, CFT, and IOP pre- and postoperatively

Patient number	Eye	Follow-up (weeks)	Type of treatment	BCVA [pre/post]	Delta BCVA [post-pre]	CFT (µm) [pre/post]	IOP (mmHg) [pre/post]
1	RE	31	A/C	[0.25/1.0] ^a	+0.75	[406/321]	[16/15]
	LE	30	A/C	[0.25/0.8] ^a	+0.55	[491/381]	[16/35]
2	RE	7	A	[0.25/0.6]	+0.35	[541/240]	[18/26]
	LE	9	A	[0.2/0.4]	+0.20	[504/210]	[18/25]
3	RE	36	A/C	[0.3/0.5]	+0.20	[291/222]	[14/15]
	LE	35	A/C	[0.6/1.0]	+0.40	[297/228]	[12/16]
4	LE	2	A/C	[0.1/0.2]	+0.10	[nd/371]	[19/19]
5	LE	8	A	[0.4/0.4]	± 0	[nd/nd]	[14/17]
6	RE	9	A/C	[0.32/0.4]	+0.08	[nd/300]	[19/21]
7	LE	13	A/C	[0.1/0.1]	± 0	[nd/253]	[17/15]
8	RE	25	A/C	[0.2/0.1]	-0.10	[nd/312]	[16/10]
9	RE	26	A/C	[0.3/0.6]	+0.30	[729/355]	[12/20]
	LE	21	A/C	[0.25/0.3]	+0.05	[661/396]	[14/21]
10	RE	37	A/C	[0.1/0.1]	± 0	[497/251]	[14/20]
	LE	36	A/C	[0.1/0.05]	-0.05	[677/427]	[14/19]

Notes: Values for last post-op follow-up visit given. ^aPreplanned cataract surgery conducted 5–6 weeks after the intravitreal injection of 190-µg FAc implant.

Abbreviations: A, prior treatment with VEGF antagonists; A/C, prior treatment with VEGF antagonists followed by a treatment with corticosteroids; BCVA, best-corrected visual acuity (decimal scale); CFT, central fovea thickness; IOP, intraocular pressure; LE, left eye; nd, no OCT data available in the registry; RE, right eye; VEGF, vascular endothelial growth factor.

Figure 1 BCVA at the preop versus the last follow-up visit for each individual patient.

Notes: Above the line: increase in BCVA. On the line: no change in BCVA. Below the line: decrease in BCVA. Mean follow-up period: 21.7 weeks (range: 2–37 weeks).

Abbreviation: BCVA, best-corrected visual acuity.

last follow-up visit. Fast improvements were also visible in the fluorescence angiograms. As an example the angiographic findings for patient number 5 (left eye) are shown in Figure 3 pre- and 2 months postinjection of FAC.

Intraocular pressure (IOP)

Three of the 15 eyes showed an increase of IOP (>7 mmHg) (Figure 4). In two patients IOP was lowered successfully by a sectorial cyclocryotherapy and/or a medical treatment

Figure 2 CFT at the preop visit versus the last follow-up visit for each individual eye.

Notes: Above the line: increase in CFT. On the line: no change in CFT. Below the line: decrease in CFT. Mean follow-up period: 21.7 weeks (range: 2–37 weeks).

Abbreviation: CFT, central fovea thickness.

with a fixed combination of IOP-lowering eyedrops (dorzolamide/timolol or brinzolamide/timolol). Cyclocryotherapy is a routine procedure used at the center for patients that do not respond sufficiently to a fixed-dose combination. The mean change in IOP was 4.1 ± 5.8 mmHg from a mean baseline value of 15.5 ± 2.3 mmHg (individual data are plotted in Table 3). Figure 4 shows the development of IOP for each individual patient at baseline versus the last follow-up visit.

In order to illustrate the overall findings, two patient cases are described more in detail. The selection was based on the length of the follow-up period: One patient (patient number 2) was selected with a short follow-up period and one patient (patient number 3) with a longer follow-up period.

Preop (August 22, 2013)

Postop (November 21, 2013)

Figure 3 Fluorescence angiographic findings for patient number 5, left eye pre- and 2 months postinjection of 190 μ g FAC. The intravitreal injection of FAC took place on September 26, 2013.

Abbreviation: FAC, fluocinolone acetonide.

Figure 4 IOP at the preop visit versus the last follow-up visit for all individual eyes. **Notes:** Above the line: increase in IOP. On the line: no change in IOP. Below the line: decrease in IOP. Mean follow-up period: 21.7 weeks (range: 2–37 weeks). **Abbreviation:** IOP, intraocular pressure.

Case reports

Case A – patient number 2

This patient is a 64-year-old female with a history of chronic DME. Systemically, the patient suffers from multiple forms of arthrosis such as gonarthrosis, omarthrosis, and arthrosis of the hands. This patient also had a long history of ophthalmic diseases: diabetic retinopathy, DME, AMD, laser capsulotomy, bilateral pseudophakia, and pars plana vitrectomy. Prior to injection of 190 µg FAc, both eyes of this patient were treated as follows: bevacizumab (four injections, left eye), ranibizumab (two injections, left eye), and bevacizumab (three injections, left eye). BCVA at baseline (last visit before FAc) was 0.25 (right eye) and 0.2 (left eye), CFT was 541 µm (right eye) and 504 µm (left eye). IOP baseline values were 18 mmHg for both eyes. Intravitreal injection of the 190-µg FAc implant was conducted in the right eye on January 15, 2014 and in the left eye on January 28, 2014.

Morphology – OCT findings

OCT showed a fast morphological improvement of DME in both eyes with a clear reduction of the magnitude of cysts. The improvements for both eyes and all follow-up visits are shown in Figure 5. Intraretinal cysts in the right eye due to DME were significantly reduced during the 7–9 weeks after injection of the FAc implant.

Best-corrected visual acuity (BCVA)

In both eyes, BCVA showed a rapid gain 1–3 weeks after the procedure: BCVA improved in the right eye from 0.25

to 0.4 and in the left eye from 0.2 to 0.3. A further gain was observed 7–9 weeks after the procedure (Figure 6).

Central fovea thickness (CFT)

CFT decreased significantly during the follow-up period in the right eye from 541 to 240 µm (–301 µm; week 7) and in the left eye from 504 to 210 µm (–294 µm; week 9) (Figure 7).

Intraocular pressure (IOP)

IOP increased from 18 mmHg at baseline to 26 mmHg in the right eye at week 7 and from 18 to 25 mmHg in the left eye at week 9. A medical treatment of increased IOP with a fixed combination dorzolamide/timolol (bid) was initiated, which reduced IOP to ≤20 mmHg.

Case B – patient number 3

This patient is a 72-year-old male with a long history of DME. Systemically the patient suffers from arterial hypertension and type 2 diabetes. Ophthalmic diseases of this patient included diabetic retinopathy, DME, and bilateral pseudophakia. Prior to injection with FAc, both eyes of this patient were treated as follows: bevacizumab (seven injections, both eyes), triamcinolone 4 mg (one injection, right eye), triamcinolone 10 mg (left eye), and triamcinolone 25 mg (six injections, both eyes). BCVA at baseline (last visit before FAc) was 0.3 (right eye) and 0.6 (left eye), CFT was 473 µm (right eye) and 297 µm (left eye). IOP baseline values were 14 mmHg (right eye) and 12 mmHg (left eye).

Morphology – OCT findings

OCT showed a fast morphological improvement of DME in both eyes with a clear reduction of the magnitude of cysts. The improvements for both eyes and all follow-up visits are shown in Figure 8. Intraretinal cysts in the right eye due to DME were significantly reduced at the first follow-up visit 3 weeks after injection of the 190-µg FAc implant. The effect was sustained up till the last follow-up visit (week 35).

Best-corrected visual acuity (BCVA)

In both eyes, BCVA showed a rapid gain within 1–3 weeks after the procedure: BCVA improved in the right eye from 0.3 to 0.5 and in the left eye from 0.6 to 1.0 (Figure 9).

Central fovea thickness (CFT)

CFT decreased significantly during the follow-up period in the right eye from 541 to 222 µm (week 35) and in the left eye from 297 to 210 µm (week 36) (Figure 10).

Figure 5 Data from patient number 2 showing OCT scans at pre- and postop visits.
Abbreviation: OCT, optical coherence tomography.

Intraocular pressure (IOP)

At week 35, IOP remained almost unchanged in the right eye (+1 mmHg from a baseline value of 14 mmHg). At week 36, IOP had increased slightly in the left eye (+4 mmHg from a baseline value of 12 mmHg). In both eyes IOP was ≤ 16 mmHg.

Figure 6 Data from patient number 2 showing BCVA at preop and postop visits.
Abbreviation: BCVA, best-corrected visual acuity.

Discussion

Beside the description of single patient reports, there is little information available on the outcome of treatment of patients with FAc under “real life” conditions. To the author’s knowledge, this is the first report of a series of cases

Figure 7 Data from patient number 2 showing CFT at preop and postop visits.
Abbreviation: CFT, central fovea thickness.

Figure 8 Data from patient number 3 showing OCT scans at pre- and postop visits.
Abbreviation: OCT, optical coherence tomography.

that were treated with FAc in a routine clinical setting. The safety and efficacy of 190- μ g FAc implant in patients with chronic DME refractory to other medical treatment options in a case series in the real world clinical setting was evaluated. In total, 15 eyes were treated from ten subjects (nine male and one female patient). Prior to treatment with FAc, all patients were treated either with a VEGF antagonist and/or

a steroid (triamcinolone, dexamethasone implant). BCVA improved in eleven eyes (73.3%; range: 0.05–0.75), remained unchanged in two eyes (13.3%), and decreased slightly in two eyes (13.3%; range: –0.05 to –0.1) at the last follow-up visit in comparison to baseline. Data from randomized, controlled studies have shown that laser photocoagulation,²⁶ and intravitreal injections of VEGF antagonists^{27,28} and

Figure 9 Data from patient number 3 showing visual acuity (BCVA) at preop and postop visits.

Abbreviation: BCVA, best-corrected visual acuity.

corticosteroids^{8,10} are efficacious and useful in the medical treatment of DME. However, these studies also show that repeated treatments are often required to control macula edema, prevent vision loss, and increase the chance of visual improvement. Furthermore, subanalyses data from two well controlled long-term clinical studies with ranibizumab (RISE and RIDE studies) show that a delayed initiation of medical treatment in chronic DME results in a small gain in visual acuity relative to those patients treated 24 months earlier.²⁹ These data indicate that the number of VEGF antagonist nonresponders (defined as patients with a gain in visual acuity

of <10 letters) should be expected in a range between 35.4% and 37.6%³⁰ based on monthly injections. For these patients that do not respond adequately to VEGF antagonists, alternative treatment options, such as FAc, are of great importance. FAc has been recently approved for the treatment of chronic DME in patients refractive to other medical treatments. A study in eyes with persistent DME demonstrated that the FAc microimplant produced improvements in visual acuity, decreased macular thickness, and fluorescein leakage that were sustained for up to 3 years.²⁴ This study confirmed the beneficial effect of FAc on the clinical outcome of DME in

Figure 10 Data from patient number 3 showing CFT at pre- and postop visits.

Abbreviation: CFT, central fovea thickness.

a real-life clinical setting. In parallel to the decrease of CFT, a gain in visual acuity was observed in 73.3% of all eyes. All patients of this registry study showed signs of a persistent DME after being treated with either VEGF antagonists and/or intravitreal corticosteroids. Interestingly even most of the latter patients with prior corticosteroid treatment showed an improvement in BCVA and CFT after the treatment with FAc. This finding may, at least in part, be explained by a different release of the active ingredient from the microimplant and different pharmacokinetics such as a sustained and constant release of the active ingredient from the matrix.

One common side effect resulting from the use of corticosteroids for the treatment of DME is the possible rise in IOP. For triamcinolone, a rise of IOP of ≥ 10 mmHg versus baseline was reported in 16% and 33% of patients treated with 1 and 4 mg respectively.²¹ In this study, three of the 15 eyes had a rise of IOP of >7 mmHg. The rise in IOP was controlled either by a sectorial cyclocryotherapy and/or a medical treatment with fixed combinations. Another known AE of corticosteroids is cataract formation. Cataract surgery was performed in 23% and 51% of eyes treated with 1 and 4 mg triamcinolone respectively.²¹ The effect of FAc on cataract formation in this case series could not be evaluated since most of the patients from this patient cohort were pseudophakic ($n=13/15$ eyes), and because one patient already had an existing cataract with removal planned for after intravitreal injection of 190- μ g FAc implant (Table 3). Furthermore, the possible differences of FAc on the visual outcomes (BCVA, CFT) in patients with DME with and without prior vitrectomy can only be speculated. First, patients with vitrectomized eyes normally show worse baseline values in both, BCVA and CFT and second, many of the patients from this small patient population were vitrectomized prior to the FAc treatment.

Conclusion

The 190- μ g FAc implant appeared efficacious and safe in the treatment of the patients with chronic DME refractive to other medical treatments in this patient population. Visual acuity improved in eleven out of 15 eyes (73.3% of cases). Distinct increases of IOP (>7 mmHg) were observed in three eyes (20% of cases) during the follow-up period which could be controlled by cyclocryotherapy ($n=1$) and/or medical treatment. The data from this registry study indicate that FAc may be an effective addition in the armamentarium for the medical treatment of chronic DME, especially for those patients refractive to other medical treatments. According to the guidelines of the German Retinological Society, a change of treatment may be considered if the BCVA does

not show an improvement of at least one line or a reduction of retina thickness of at least 10% during the last 3 months postinjection of VEGF antagonists. It is necessary to closely monitor the further development of all of these patients during the next several months in order to evaluate the further development of all parameters and be able to collect additional information of the longer-term effects of the 190- μ g FAc implant.

Acknowledgments

I acknowledge the support provided by Friedemann Kimmich, PhD (Eyecons, Karlsruhe, Baden-Württemberg, Germany) and Albert Augustin, MD (Augenlinik Städtisches Klinikum, Karlsruhe, Baden-Württemberg, Germany). The publication of this article and editorial assistance was funded by Alimera Sciences Ltd. The views and opinions expressed in the article are those of the authors and not necessarily those of Alimera Sciences Ltd.

Disclosure

The author reports no conflicts of interest in this work.

References

1. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: XV. The long-term incidence of macular edema. *Ophthalmology*. 1995;102(1):7–16.
2. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012;35:556–564.
3. Ferris FL III, Patz A. Macular edema. A complication of diabetic retinopathy. *Surv Ophthalmol*. 1984;28(Suppl):452–461.
4. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. *Surv Ophthalmol*. 2009;54:1–32.
5. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. *Ophthalmology*. 1998;105:998–1003.
6. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. *Ophthalmology*. 1998;105:1801–1815.
7. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. *Ophthalmology*. 1995;102:647–661.
8. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. *Ophthalmology*. 2004;111(2):218–224; discussion 224–225.
9. Tang J, Kern TS. Inflammation in diabetic retinopathy. *Prog Retin Eye Res*. 2011;30(5):343–358.
10. Jonas JB, Kamppeiter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. *J Ocul Pharmacol Ther*. 2006;22(3):200–207.
11. Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. *Ophthalmic Res*. 2006;38(4):218–245.
12. Folkman J. Angiogenesis and apoptosis. *Semin Cancer Biol*. 2003;13(2):159–167.

13. Nakano T, Ohara O, Teraoka H, Arita H. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. *J Biol Chem*. 1990;265(21):12745–12748.
14. Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. In: Sears M, Tarkkanen A, editors. *Surgical Pharmacology of the Eye*. New York, NY: Raven Press; 1985:83–133.
15. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood aqueous barrier breakdown. *Exp Eye Res*. 2005;80:249–258.
16. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. *Am J Ophthalmol*. 2002;133:70–77.
17. Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. *Ophthalmology*. 2013;120:583–587.
18. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a doublemasked, placebo-controlled, randomized clinical trial. *Ophthalmology*. 2006;113:1533–1538.
19. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. *Ophthalmology*. 2002;109:920–927.
20. Bressler NM, Edwards AR, Beck RW, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. *Arch Ophthalmol*. 2009;127:1566–1571.
21. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. *Ophthalmology*. 2008;115:1447–1449.
22. Campochiaro PA, Hafiz G, Shah SM, et al; FAMOUS Study Group. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. *Ophthalmology*. 2010;117:1393–1399.
23. ILUVIEN® [summary of product characteristics]. Last updated on eMC 18-Feb-2014. Available from: <https://www.medicines.org.uk/emc/medicine/27636>. Accessed July 24, 2014.
24. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. *Ophthalmology*. 2012;119:2125–2132.
25. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants. *Ophthalmology*. 2014;121:1892–1903.
26. Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. *Ophthalmologica*. 2007;221:95–102.
27. Nguyen QD, Shah SM, Khwaja AA, et al. Two year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. *Ophthalmology*. 2010;117:2146–2151.
28. Bressler NM, Varma R, Suñer JJ, et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. *Ophthalmology*. 2014;121(12):2461–2472.
29. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. *Ophthalmology*. 2013;120:2013–2022.
30. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. *Ophthalmology*. 2012;119:789–801. Supplemental material (Table 6). Available from: <http://www.aaojournal.org/cms/attachment/2005446053/2023774732/mmc1.pdf>. Accessed August 22, 2014.

Clinical Ophthalmology

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on

Submit your manuscript here: <http://www.dovepress.com/clinical-ophthalmology-journal>

Dovepress

PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.